Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Background and Aim: As one of the second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors, afatinib brings survival benefits to patients with common and rare EGFR mutations. This study aimed to compare the effectiveness and safety of 30 and 40 mg of afatinib in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ziyu, Du, Xin, Chen, Ken, Li, Shanshan, Yu, Zhiheng, Wu, Ziyang, Yang, Li, Chen, Dingding, Liu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666963/
https://www.ncbi.nlm.nih.gov/pubmed/34912228
http://dx.doi.org/10.3389/fphar.2021.781084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666963/
https://www.ncbi.nlm.nih.gov/pubmed/34912228
http://dx.doi.org/10.3389/fphar.2021.781084

Ejemplares similares